Table 2.

Univariate and multivariate analyses for progression-free survival

Variable	Univariate	P	Multivariatea	P
	HR (95% CI)		HR (95% CI)
Age (range)	3.10 (0.98–10.03)	0.055
PSA at diagnosis (range)	2.60 (0.71–7.39)	0.14
Gleason score
≤7	Ref
8–10	2.68 (1.26–6.94)	0.0086*
cT stage
T2/3a	Ref
T3b	1.19 (0.64–2.13)	0.57
T4	2.25 (1.36–3.72)	0.0016*
cN stage
N0	Ref
N1	1.56 (0.98–2.56)	0.061
cM stage
M1a	Ref
M1b	1.40 (0.62–3.98)	0.45
M1c	0.32 (0.017–1.98)	0.24
Glucose
<126 mg/dL	Ref		ref
≥126 mg/dL	1.61 (0.98–2.58)	0.059	1.06 (0.61-1.79)	0.83
Total cholesterol
<220 mg/dL	Ref		Ref
≥220 mg/dL	0.91 (0.51–1.53)	0.73	1.21 (0.65–2.14)	0.53
Triglyceride
<150 mg/dL	Ref		Ref
≥150 mg/dL	0.97 (0.57–1.58)	0.97	1.28 (0.74–2.14)	0.37
Body mass index
<25 kg/m2	Ref		Ref
≥25 kg/m2	0.81 (0.44–1.38)	0.45	0.89 (0.47–1.56)	0.69
DM
Absence	Ref		Ref
Presence	1.94 (1.17–3.12)	0.011*	1.25 (0.69–2.20)	0.45
Dyslipidemia
Absence	Ref		Ref
Presence	1.10 (0.59–1.92)	0.75	1.31 (0.67–2.41)	0.42

*Statistically significant.

^aAdjusted by age, PSA at diagnosis, Gleason score, and clinical stage.